Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$19.30

0.88 (4.78%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22

Alkermes making some positive changes, says Piper Jaffray

Piper Jaffray analyst Danielle Brill said she believes Alkermes "is making some positive changes" with its restructuring plans, adding that the company's need for pipeline growth was reinforced by "another disappointing revision" to its outlook for Aristada revenue. In Q3, Aristada's slower than anticipated growth was offset by higher than anticipated Sustenna royalties, helping the company to beat revenue expectations and maintain its FY19 guidance, Brill noted. She doubts that the company's Vumerity and 3831 opportunities will offset upcoming royalty expirations, leading her to keep a Neutral rating on the stock, but Brill added that she could get more constructive on Alkermes if it makes promising pipeline additions.

  • 23

    Oct

  • 06

    Nov

ALKS Alkermes
$19.30

0.88 (4.78%)

07/30/19
HCWC
07/30/19
NO CHANGE
Target $28
HCWC
Neutral
Alkermes settlement close to best-case scenario, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao says Alkermes' (ALKS) settlement and license agreement with Amneal Pharmaceuticals (AMRX) provides a "measure of needed visibility." There was some investor nervousness coming into the hearing and this settlement "represents close to a best-case scenario for Alkermes," Tsao tells investors in a research note. Vivitrol's growth has slowed but 12% volume growth in Q2 indicates the franchise can continue to be a contributor for the foreseeable future, adds the analyst. Tsao thinks the bull thesis for Alkermes hinges largely on the prospects for ALKS-4230. The update that patients on ALKS-4230 appear to avoid capillary leak syndrome, which has limited the utility of IL-2 therapies in the past, is important, according to Tsao. He keeps a Neutral rating on Alkermes with a $28 price target.
07/30/19
JPMS
07/30/19
NO CHANGE
JPMS
Overweight
Alkermes, Biogen data a positive, but questions remain, says JPMorgan
JPMorgan analyst Cory Kasimov views the data this morning from Alkermes (ALKS) and Biogen (BIIB) as an incremental positive but he believes commercial questions remain for Vumerity. The analyst has an Overweight rating on Alkermes and Neutral rating on Biogen. How doctors will view this dataset and how aggressive Biogen will be in launching Vumerity in the face of questions regarding Tecfidera's ultimate runway are the next key questions, Kasimov tells investors in a research note. However, he calls this morning's news a "good-to-see outcome."
07/30/19
PIPR
07/30/19
NO CHANGE
PIPR
Neutral
Piper says Alkermes scores 'back-to-back wins' with settlement, Biogen data
Piper Jaffray analyst Danielle Brill said Alkermes (ALKS) has scored "back-to-back wins" with its announcement yesterday that it settled the ongoing Vivitrol patent dispute with Amneal (AMRX) and the news this morning that BIIB098 showed a statistically significant improvement on GI tolerability versus Tecfidera in a head-to-head Phase 3 trial. She still questions how meaningful the improvement in GI tolerability actually is, but thinks the drug may become a priority for partner Biogen (BIIB), Brill tells investors. The analyst, who views the news of the last two days as net positive for Alkermes, maintains her concerns about long-term value creation and the company's "dry pipeline," she said. Brill keeps a Neutral rating on Alkermes shares.
09/05/19
MSCO
09/05/19
UPGRADE
Target $20
MSCO
Equal Weight
Alkermes upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst David Risinger upgraded Alkermes to Equal Weight from Underweight while lowering his price target for the shares to $20 from $30. The stock has underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent, Risinger tells investors in a research note. Although cancer pipeline candidate ALKS 4230 could still disappoint, consensus expectations are low due to a questionable profile, adds the analyst. He believes Alkermes' long-term risk to royalty streams is balanced by its pipeline or cost savings optionality at current share levels.

TODAY'S FREE FLY STORIES

KDMN

Kadmon

$3.56

-0.155 (-4.18%)

20:59
11/13/19
11/13
20:59
11/13/19
20:59
Syndicate
Kadmon 26M share Spot Secondary priced at $3.40 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

UBER

Uber

$26.70

(0.00%)

20:17
11/13/19
11/13
20:17
11/13/19
20:17
Hot Stocks
Uber chairman buys 35K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

ALPN

Alpine Immune Sciences

$2.49

-0.06 (-2.35%)

19:47
11/13/19
11/13
19:47
11/13/19
19:47
Recommendations
Alpine Immune Sciences analyst commentary at Piper Jaffray »

Alpine Immune Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

19:45
11/13/19
11/13
19:45
11/13/19
19:45
Hot Stocks
HP Inc. raises quarterly dividend to 17.6c from 16.0c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

RETA

Reata Pharmaceuticals

$187.00

4.48 (2.45%)

19:18
11/13/19
11/13
19:18
11/13/19
19:18
Syndicate
Reata Pharmaceuticals 2.4M share Secondary priced at $183.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

BCRX

BioCryst

$1.60

-0.185 (-10.39%)

19:13
11/13/19
11/13
19:13
11/13/19
19:13
Syndicate
BioCryst 37.93M share Secondary priced at $1.45 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

19:03
11/13/19
11/13
19:03
11/13/19
19:03
Periodicals
U.S. lawmaker frustrated with Google's bid to buy Fitbit, Reuters says »

U.S. Representative David…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

FB

Facebook

$193.20

-1.27 (-0.65%)

AMZN

Amazon.com

$1,753.84

-24.49 (-1.38%)

AAPL

Apple

$264.52

2.63 (1.00%)

FIT

Fitbit

$6.86

-0.105 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

PING

Ping Identity

$16.50

-0.25 (-1.49%)

, SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

18:51
11/13/19
11/13
18:51
11/13/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ping…

PING

Ping Identity

$16.50

-0.25 (-1.49%)

SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

PRSP

Perspecta

$27.79

-0.18 (-0.64%)

HI

Hillenbrand

$31.53

-1 (-3.07%)

CPA

Copa Holdings

$107.71

1.89 (1.79%)

PSNL

Personalis

$10.92

0.745 (7.33%)

TRQ

Turquoise Hill

$0.46

-0.006 (-1.29%)

CATS

Catasys

$14.60

-0.47 (-3.12%)

LTRX

Lantronix

$3.15

0.06 (1.94%)

SLGG

Super League Gaming

$3.06

0.07 (2.34%)

BZH

Beazer Homes

$14.67

0.21 (1.45%)

CSCO

Cisco

$48.44

0.06 (0.12%)

TTEK

Tetra Tech

$88.38

1.24 (1.42%)

NTAP

NetApp

$60.04

-0.08 (-0.13%)

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 14

    Nov

BZH

Beazer Homes

$14.67

0.21 (1.45%)

18:49
11/13/19
11/13
18:49
11/13/19
18:49
Earnings
Beazer Homes reports Q4 EPS 8c, two estimates 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HT

Hersha Hospitality

$13.84

-0.23 (-1.63%)

18:46
11/13/19
11/13
18:46
11/13/19
18:46
Hot Stocks
Hersha Hospitality CEO: Airnb has definitely had an impact »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

FICO

Fair Isaac

$336.80

2.56 (0.77%)

18:40
11/13/19
11/13
18:40
11/13/19
18:40
Hot Stocks
Fair Isaac director sells 6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

18:33
11/13/19
11/13
18:33
11/13/19
18:33
Hot Stocks
ProPetro discloses U.S. SEC probe »

ProPetro has filed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

DXCM

DexCom

$202.81

-3.35 (-1.63%)

, WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

18:25
11/13/19
11/13
18:25
11/13/19
18:25
Hot Stocks
DexCom CEO: The type 2 diabetes business is just getting started »

In an interview on…

DXCM

DexCom

$202.81

-3.35 (-1.63%)

WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 22

    Nov

EQS

Equus II Inc

$1.55

(0.00%)

18:19
11/13/19
11/13
18:19
11/13/19
18:19
Hot Stocks
Equus reports Q3 NAV per share of $3.63 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSYS

Stratasys

$18.35

-2.39 (-11.52%)

18:04
11/13/19
11/13
18:04
11/13/19
18:04
Recommendations
Stratasys analyst commentary at Piper Jaffray »

Stratasys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GLD

SPDR Gold Shares

$137.98

0.56 (0.41%)

18:03
11/13/19
11/13
18:03
11/13/19
18:03
Hot Stocks
SPDR Gold Shares holdings fall to 896.77MT from 897.09MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

17:57
11/13/19
11/13
17:57
11/13/19
17:57
Hot Stocks
Copa Holdings reports October capacity down 4.8%, traffic down 1.4% »

Copa Holdings released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

CCI

Crown Castle

$131.34

0.67 (0.51%)

17:51
11/13/19
11/13
17:51
11/13/19
17:51
Hot Stocks
Crown Castle chairman buys 10.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

17:48
11/13/19
11/13
17:48
11/13/19
17:48
Periodicals
Google confirms several features not available on Stadia at launch, Kotaku says »

During an AMA on Reddit,…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

17:44
11/13/19
11/13
17:44
11/13/19
17:44
Hot Stocks
BAE Systems awarded maximum $270.6M Navy contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBT

HBT Financial

$16.99

0.18 (1.07%)

17:38
11/13/19
11/13
17:38
11/13/19
17:38
Hot Stocks
HBT Financial director Patrick Busch buys over 13K shares of company stock »

HBT Financial director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$299.90

3.82 (1.29%)

, QGEN

Qiagen

$35.52

3.26 (10.11%)

17:38
11/13/19
11/13
17:38
11/13/19
17:38
Periodicals
Thermo Fisher considering purchase of Qiagen, Bloomberg reports »

Thermo Fisher (TMO) is…

TMO

Thermo Fisher

$299.90

3.82 (1.29%)

QGEN

Qiagen

$35.52

3.26 (10.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

AOBC

American Outdoor Brands

$7.90

0.22 (2.86%)

17:36
11/13/19
11/13
17:36
11/13/19
17:36
Conference/Events
American Outdoor Brands to hold a conference call »

President & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.